"In the largest, most comprehensive, nationwide study to examine the prevalence of allergies from early childhood to old age, scientists from the National Institutes of Health report that allergy prevalence is the same across different regions "...
Karbinal ER Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Karbinal ER (carbinoxamine maleate) is used to treat a wide variety of allergic reactions, including seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, allergic skin manifestations of urticaria and angioedema, dermatographism, as therapy for anaphylactic reactions, and to improve the severity of allergic reactions to blood or plasma. Common side effects of Karbinal ER can include sleepiness, dizziness, disturbed coordination, abdominal pain, and thickening of bronchial secretions.
Karbinal ER is available as an extended-release oral suspension of 4 mg carbinoxamine maleate per 5 mL. Dosage depends of the age of the patient. Karbinal ER may interact with monoamine oxidase inhibitors (MAOIs), alcohol, hypnotics, sedatives, tranquilizers or other substances that suppress the central nervous system. Tell your doctor all medications you use. It is unknown if Karbinal ER causes fetal harm when administered to a pregnant woman or if it can affect a woman's ability to reproduce, and should be given to a pregnant woman only if clearly needed. Karbinal ER should not be given to women who are currently breastfeeding.
Our Karbinal ER (carbinoxamine maleate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Karbinal ER FDA Prescribing Information: Side Effects
Use of Karbinal ER may result in decreased mental alertness with impaired mental or physical abilities [see WARNINGS AND PRECAUTIONS].
The most frequent adverse reactions include: sedation, sleepiness, dizziness, disturbed coordination, epigastic distress, and thickening of bronchial secretions. In clinical use, younger children and older adults may be particularly sensitive to adverse reactions [see Pediatric Use and Geriatric Use].
The following adverse reactions, listed by body system, have been identified in case reports and during the use of carbinoxamine in observational studies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Central Nervous System: Fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, constipation.
Laboratory: Increase in uric acid levels.
Respiratory: Tightness of chest and wheezing, nasal stuffiness.
Urogenital: Urinary frequency, difficult urination, urinary retention, early menses.
Read the entire FDA prescribing information for Karbinal ER (Carbinoxamine Maleate Extended-Release Oral Suspension) »
Additional Karbinal ER Information
Report Problems to the Food and Drug Administration
Allergies & Asthma
Improve treatments & prevent attacks.